Total
0
Shares
Source: Little Green Pharma
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medicinal cannabis company Little Green Pharma (LGP) has welcomed the Therapeutic Goods Administration’s (TGA) regulatory changes to cannabidiol (CBD)
  • The TGA has down-scheduled some CBD products and also increased the daily maximum dosage limit
  • This decision means from early next year registered CBD products can be dispensed over-the-counter without the need for a prescription
  • LGP has congratulated the TGA for the change, stating the down-scheduling will make medicinal cannabis more widely available across Australia
  • Shares in Little Green Pharma have ended the day down a slight 0.83 per cent trading at 59.5 cents each

Little Green Pharma (LGP) has welcomed the Therapeutic Goods Administration’s (TGA) wide-ranging changes to cannabidiol (CBD) regulation.

The medicinal cannabis business has joined other ASX-listed companies in congratulating the TGA for making changes to the rules around dispensing CBD.

The regulatory body has down-scheduled some CBD products to pharmacist-only medications and increased the daily maximum dosage limit to 150 mg per day.

It’s an important change, as the down-scheduling means from early next year registered CBD products can be dispensed over-the-counter without the need for a prescription.

Commenting on the TGA’s decision, Little Green Pharma Managing Director Fleta Solomon said the change should benefit the entire industry.

“This final scheduling decision demonstrates both the TGA’s commitment to patient safety and product quality as well as its appreciation of prescriber and patient needs,” Fleta said.

“We wish to congratulate the TGA on its decision and look forward to the significant benefits it will bring to both Australian patients and prescribers and the Australian medicinal cannabis industry as a whole.”

As well as congratulating the TGA for its decision, Little Green has also flagged plans to potentially register one or two of its cannabis oil medicines.

The company said the TGA’s planned increase of the maximum daily dose will give it more confidence to progress down the path of Australian Register of Therapeutic Goods (ARTG) CBD medicine registrations.

Shares in Little Green Pharma have ended Wednesday’s session down 0.83 per cent at 59.5 cents each.

LGP by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.